Perthera AI’s proven data exploration, analytics, optimization and care management platform is now available for cancer centers to use for their own data analysis.
—Chip Petricoin, Ph.D.
MCLEAN, Virginia, USA, June 6, 2022 /EINPresswire.com/ — Perthera, a leader in AI-driven precision oncology solutions, today announced the immediate availability of the Perthera AI Analytics platform at of the ASCO ’22 conference in Chicago, Illinois. Perthera AI Analytics brings the power of Perthera’s proven artificial intelligence, machine learning, data mining and advanced analytics capabilities to oncologists and research staff to enable them to leverage their own data of patients to identify trends; ultimately improving clinical trial enrollment and patient care management. The Perthera AI Analytics platform is offered free of charge to cancer centers.
Perthera has built a market-leading AI analytics platform that draws insights from its Therapeutic Intelligence Engine, built over a decade and comprised of databases updated in real time as new available patient data, proprietary artificial intelligence and machine learning algorithms, and over 50,000 heuristic rules. The platform has been shown in peer-reviewed research to significantly improve overall patient survival and advance clinical research efforts for physicians and their institutions. At ASCO ’22, Patrick Lee of Cedars Sinai presented a retrospective analysis of patient data seen at Cedars Sinai and Perthera’s RWE database which, using the analytics solution, established a new biomarker signature of treatment response in pancreatic neuroendocrine disease. (#ASCO22 Poster #4124)
“Two years ago, Perthera and our clinician colleagues published a landmark study in Lancet Oncology showing that Perthera’s AI operating system, when implemented, identified treatment options that lead to dual increased survival for patients with pancreatic cancer,” said Emanuel “Chip” Petricoin. , co-founder and scientific director of Perthera. “This research continues today and now the power of the Perthera AI Analytics platform is fully available to cancer centers nationwide.”
Using the Perthera AI Analytics platform, oncologists and researchers will be able to harness the proven power of the analytics solution designed to connect to comprehensive cancer center databases. Perthera AI Analytics will advance the capabilities of cancer centers by providing:
• Multi-omics patient matching algorithms and analysis
• Real-time correlations based on results
• Population-based biomarker analysis
• Results corresponding to the treatment
• Ability to correlate n-dimensional data to identify patient cohorts missed by traditional methods
• Optimization of enrollment in clinical trials
• Identification of new targets such as biomarkers and other drug targets
• Patient care management
Partnership with Perthera:
Cancer centers can partner with Perthera for free access to Perthera AI Analytics. The analysis solution connects to the cancer center’s various databases, allowing oncologists and researchers to immediately harness the power of the platform. Perthera AI will integrate the data and results into the broader Perthera Intelligence solution and make this data available to the cancer center’s own researchers and other third parties.
Learn more about Perthera AI Analytics:
Visit us at booth 27102 at ASCO 2022 for a demo of the Perthera AI Analytics platform and to start the conversation; or call Perthera at (833) 781-7810; or email [email protected]
Founded in 2012, Perthera is a leader in AI-driven precision oncology solutions. Used in more than 250 cancer treatment centers across the United States, Perthera’s proprietary AI-powered analytics solution provides insights to thousands of oncologists across the country. With Perthera AI Insights, oncologists have access to the latest treatment options and clinical trial information. This information, based on the integration of the patient’s medical, therapeutic and molecular information, allows oncologists to offer their patients the treatment options best suited to their unique cancer types, with the ultimate goal of improving survival outcomes. global and without progression.
Albert Kelley, CEO
write to us here
Visit us on social media: